BYSI Form 4: Decheng Funds Sell 4,870 Shares; 4.41M Shares Still Held
Rhea-AI Filing Summary
Decheng Capital-affiliated funds and Dr. Xiangmin Cui reported sales of BeyondSpring Inc. (BYSI) ordinary shares in late August and early September 2025. The filing shows Decheng Capital China Life Sciences USD Fund III, L.P. sold 800 shares on 08/29/2025, 2,800 shares on 09/02/2025 and 1,270 shares on 09/03/2025 at weighted-average prices in the $1.67–$1.84 range, reducing Fund III’s reported beneficial ownership to 1,904,755 shares.
Other related entities retain beneficial holdings: Decheng Capital China Life Sciences USD Fund II, L.P. holds 1,617,409 shares and Decheng Capital Global Healthcare Fund (Master), LP holds 891,734 shares. Footnotes explain the holdings are held directly by the named funds, GP entities and Dr. Cui may be deemed to beneficially own such securities, and the reported prices are weighted averages across multiple transactions.
Positive
- Continued significant beneficial ownership: Combined reported holdings across the named funds equal 4,413,898 shares (1,904,755; 1,617,409; 891,734), showing retained exposure.
- Transparent disclosures: Footnotes provide weighted-average price ranges and state availability of per-price breakouts on request, enhancing clarity.
Negative
- Insider sales reported: Decheng Capital China Life Sciences USD Fund III executed sales totaling 4,870 shares on 08/29/2025–09/03/2025 at weighted-average prices between $1.67 and $1.84.
- Potential perception risk: While not quantified here, insider disposals can be viewed negatively by some investors even when disclosed and limited in size.
Insights
TL;DR: Affiliated funds executed modest sales while maintaining multi-million share holdings; transactions are disclosed and routine.
The Form 4 discloses small, sequential disposals by Fund III totaling 4,870 shares executed over three dates with weighted-average prices reported in the $1.67–$1.84 range. The disclosure is detailed with footnotes clarifying weighted-average pricing and the chain of beneficial ownership through GP entities and Dr. Cui. For investors, the filing provides transparent reporting of insider sales but does not indicate a change in control or a material reduction in aggregate beneficial ownership among the affiliated funds, which together report 4,413,898 shares remaining registered to the listed entities.
TL;DR: Proper Form 4 mechanics and disclaimers are present; ownership chains and weighted-price disclosures reduce ambiguity.
The filing includes customary explanatory footnotes stating that GP entities and the manager may be deemed beneficial owners while disclaiming direct ownership beyond pecuniary interest. Weighted-average price ranges and the undertaking to provide breakouts on request fulfill disclosure norms. This structure aids compliance review and clarifies which vehicles hold shares, supporting transparency for shareholders and regulators.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Ordinary Shares | 1,270 | $1.81 | $2K |
| Sale | Ordinary Shares | 2,800 | $1.78 | $5K |
| Sale | Ordinary Shares | 800 | $1.74 | $1K |
| holding | Ordinary Shares | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Footnotes (1)
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.72 to $1.80 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.67 to $1.84 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.79 to $1.84 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. These securities are held directly by Decheng Capital China Life Sciences USD Fund II, L.P. ("Fund II"). Decheng Capital Management II (Cayman), LLC ("GP II") is the general partner of Fund II. Dr. Cui is the manager of GP II. Each of Fund II, GP II and Dr. Cui may be deemed to beneficially own the securities held by Fund II. Each of GP II and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. These securities are held directly by Decheng Capital Global Healthcare Fund (Master), LP ("Healthcare"). Decheng Capital Global Healthcare GP, LLC ("Healthcare GP") is the general partner of Healthcare. Dr. Cui is the manager of Healthcare GP. Each of Healthcare GP and Dr. Cui may be deemed to beneficially own the securities held by Healthcare. Each of Healthcare GP and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein.
